Reports

Ideas That Generate Results

Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis

Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Aug, 2018| No. of Pages : 110

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1800.00
CD-ROM Mail Delivery
US$ 1900.00
Hard Copy Mail Delivery
US$ 1900.00
Electronic Access - Multi-User License
US$ 2500.00
 List of Figures:
 
Figure 4-1: Global - T-Cell Immunotherapy Market for Cancer (Million US$), 2018 & 2022
Figure 5-1: Global - CAR T-Cell Immunotherapy Market for Cancer (Million US$), 2018 & 2022
Figure 6-1: Kymriah - Estimated Sales Forecast (Million US$), 2018 & 2022
Figure 6-2: Yescarta - Estimated Sales Forecast (Million US$), 2018 & 2022
Figure 7-1: Global - Breakup of Cancer Prevalence by Region (%), 2015
Figure 7-2: Global - Breakup of Cancer Prevalence by Region (%), 2025
Figure 8-1: Global - T-Cell Immunotherapy Pipeline Analysis by Vectors (%), 2017 
Figure 8-2: Global - T-Cell Immunotherapy Pipeline Analysis by Phase (%), 2017
Figure 8-3: Global - T-Cell Immunotherapy Pipeline Analysis by Therapeutic Indication (%), 2017
Figure 8-4: Global - T-Cell Immunotherapy Pipeline Analysis by Technology (%), 2017
Figure 8-5: Global - T-Cell Immunotherapy Pipeline Analysis by Key Players (%), 2017
Figure 8-6: Global - T-Cell Immunotherapy Pipeline Analysis by Geography (%), 2017
Figure 9-1: US - CAR T-Cell Immunotherapy Potential Market for Cancer (Billion US$), 2018 & 2022
Figure 9-2: Europe - CAR T-Cell Immunotherapy Potential Market for Cancer (Billion US$), 2018 & 2022
 
List of Tables:
 
Table 4-1: Global - Major Venture Capitalist Investment in T-Cell Immunotherapy (Million US$), 2014-2017
Table 4-2: Global - Major IPO Raised in T-Cell Immunotherapy (Million US$), 2014-2017
Table 4-3: Global - Acquisitions and Collaborations in T-Cell Immunotherapy (Million US$), 2014-2017
Table 7-1: Global - Cancer Prevalence (Million), 2015 & 2025
Table 7-2: Global - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-3: North America - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-4: Europe - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-5: Asia-Pacific - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-6: Rest of the World - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-7: Global - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-8: North America - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-9: Europe - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-10: Asia-Pacific - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-11: Rest of the World - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-12: Global - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-13: North America - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-14: Europe - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-15: Asia-Pacific - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-16: Rest of the World - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-17: Global - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-18: North America - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-19: Europe - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-20: Asia-Pacific - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-21: Rest of the World - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-22: Global - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-23: North America - Bladder Cancer Prevalence (‘000), 2015 & 2025 
Table 7-24: Europe - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-25: Asia-Pacific - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-26: Rest of the World - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-27: Global - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-28: North America - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-29: Europe - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-30: Asia-Pacific - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-31: Rest of the World - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-32: Global - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-33: North America - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-34: Europe - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-35: Asia-Pacific - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-36: Rest of the World - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-37: Global - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-38: North America - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-39: Europe - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-40: Asia-Pacific - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-41: Rest of the World - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-42: Global - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 7-43: North America - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 7-44: Europe - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 7-45: Asia-Pacific - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 7-46: Rest of the World - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 8-1: Global T-Cell Immunotherapy Pipeline by Industry
Table 8-2: Global T-Cell Immunotherapy Pipeline by Research Collaborations
Table 10-1: Adaptimmune Therapeutics plc - Revenue (Million US$), 2015 & 2016
Table 10-2: Adaptimmune Therapeutics plc - T-Cell Immunotherapy Pipeline
Table 10-3: Juno Therapeutics, Inc. - Revenue (Million US$), 2015 & 2016
Table 10-4: Juno Therapeutics, Inc. - T-Cell Immunotherapy Pipeline
Table 10-5: Gilead Sciences, Inc. - Total Revenue (Million US$), 2014, 2015 & 2016
Table 10-6: Gilead Sciences, Inc. - T-Cell Immunotherapy Product Portfolio
Table 10-7: Gilead Sciences, Inc. - T-Cell Immunotherapy Pipeline
Table 10-8: Novartis - Net Sales (Million US$), 2014, 2015 & 2016
Table 10-9: Novartis - T-Cell Immunotherapy Product Portfolio
Table 10-10: Novartis - T-Cell Immunotherapy Pipeline
Table 10-11: Tessa Therapeutics Pte Ltd. - T-Cell Immunotherapy Pipeline
Table 10-12: Gradalis, Inc. - T-Cell Immunotherapy Pipeline
Table 10-13: Immunovative Therapies, Ltd. - T-Cell Immunotherapy Pipeline
Table 10-14: Iovance Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline
Table 10-15: Atara Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline
Table 10-16: Celgene Corporation - Total Revenue (Million US$), 2014, 2015 & 2016 
Table 10-17: Celgene Corporation - T-Cell Immunotherapy Pipeline
Table 10-18: Cellular Biomedicine Group - Net Sales & Revenue (Million US$), 2014, 2015 & 2016
Table 10-19: Cellular Biomedicine Group - T-Cell Immunotherapy Pipeline
Table 10-20: GlaxoSmithKline plc. - Group Turnover (Million US$), 2014, 2015 & 2016
Table 10-21: GlaxoSmithKline plc. - T-Cell Immunotherapy Pipeline
Table 10-22: Immunocore Ltd. - T-Cell Immunotherapy Pipeline
Table 10-23: Inovio Pharmaceuticals, Inc. - Total Revenue (Million US$), 2014, 2015 & 2016
Table 10-24: Inovio Pharmaceuticals, Inc. - T-Cell Immunotherapy Pipeline
Table 10-25: Cell Medica - T-Cell Immunotherapy Pipeline
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.